California Pharmas Spar Over Chinese Licensing
The legal wrangling between two California biopharmaceutical companies over the licensing of a cancer treatment in China has grown more intense with the filing of a counter-complaint....To view the full article, register now.
Already a subscriber? Click here to view full article